Imagion Biosystems has released Appendix 3Z Final Director’s Interest Notice. Read the Final Director’s Interest Notice.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal